Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
0.68505
+0.0141 (2.09%)
At close: Nov 18, 2026, 4:00 PM EST
0.6797
-0.0054 (-0.78%)
After-hours: Nov 18, 2026, 4:45 PM EST
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2026, Radiopharm Theranostics had annual revenue of 12.87M AUD, down -1.05%. Radiopharm Theranostics had revenue of 6.66M in the half year ending June 30, 2026.
Revenue (ttm)
12.87M AUD
Revenue Growth
-1.05%
P/S Ratio
0.98
Revenue / Employee
918,938 AUD
Employees
14
Market Cap
8.74M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 12.87M | -136.84K | -1.05% |
| Jun 30, 2025 | 13.00M | 11.41M | 716.81% |
| Jun 30, 2024 | 1.59M | -4.62M | -74.37% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 33.65M |
| Palatin Technologies | 4.70M |
| Vistagen Therapeutics | 2.38M |
| Daré Bioscience | 1.41M |
| BioLineRx | 1.39M |
| Lexaria Bioscience | 194.00K |
| Lisata Therapeutics | 100.00K |
RADX News
- 1 day ago - Radiopharm Theranostics Transcript: Bell Potter Healthcare Conference - Transcripts
- 2 days ago - Radiopharm announces data from RAD101 study - TheFly
- 6 days ago - Radiopharm Theranostics Transcript: Deutsche Bank Virtual Investor Conference - Transcripts
- 10 days ago - Radiopharm Theranostics Limited - Depositary Receipt Price Target Increased by 10.97% to $14.67 - Nasdaq
- 14 days ago - Radiopharm Theranostics aligns with FDA on single Phase 3 trial for RAD101 - TheFly
- 14 days ago - Radiopharm Theranostics aligns with FDA on single Phase 3 trial for RAD101 - TheFly
- 14 days ago - Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases - GlobeNewsWire
- 14 days ago - Radiopharm Aligns With FDA On Single Pivotal Phase 3 RAD101 Trial For Brain Metastases - Nasdaq